SHUKRA
PHARMACEUTICALS LTD.

12th August, 2026

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on Wednesday, 12th August, 2026
Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at their meeting held today i.e. 12th August, 2026 at the Registered Office of the Company ***inter-alia*** has, considered and approved the following: -

Un-Audited Financial Results of the Company for the First Quarter ended June 30, 2026, along with the Auditors' Limited Review Reports in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations.

These results have been duly reviewed by the Audit Committee and audited by M/s Shah Sanghvi and Associates, Chartered Accountants (FRN:140107W), Statutory Auditors of the Company.

(*The copies of the aforesaid Standalone and consolidated Financial Results along with the limited review report are enclosed herewith.*)

Reviewed other Business of the Company.

The Board Meeting commenced at 1:30 p.m. and concluded at 2:30 p.m.

You are requested to take the above information on records and disseminate the same on your respective websites.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited REG. NO.: 019079

Shivkant Dhakad
Company Secretary and compliance officer
Membership Number: A80894

Encl.: a/a

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317
Email : info@shukrapharmaceuticals.com | Website : www.shukrapharmaceuticals.com

SHUKRA PHARMACEUTICALS LIMITED
CIN: L24231GJ1993PLC019079
3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054
Email : info@shukrapharmaceuticals.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Sr. No.	Particulars	QUARTER ENDED 30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	YEAR ENDED 31.03.2026 (Audited)
1	**Income from Operations**				
I	Revenue from Operations	2,352.23	630.29	539.11	5,670.61
	(a) Net Sales/ Income from Operations	**2,352.23**	**630.29**	**539.11**	**5,670.61**
II	Other Income	53.97	94.72	110.97	458.48
	Total Income from Operations (I+II)	**2,406.20**	**725.01**	**650.08**	**6,129.10**
2	**Expenses**				
	(a) Cost of materials consumed	125.46	669.03	(124.85)	1,945.02
	(b) Purchase of Stock-in Trade	-	-	-	-
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	(279.00)	(75.00)	201.88	(360.12)
	(d) Employee Benefit Expenses	241.53	37.18	182.49	703.72
	(e) Finance Cost	42.95	25.83	26.81	109.30
	(f) Depreciation & Amortisation Expenses	107.40	100.75	78.72	344.27
	(g) Other Expenses	143.63	(69.53)	147.71	509.62
	Total Expenses	**381.97**	**688.25**	**512.78**	**3,251.81**
3	**Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)**	**2,024.23**	**36.75**	**137.30**	**2,877.29**
4	Exceptional Items	-	-	-	-
5	**Profit / (Loss) before Extra ordinary items and Tax (3-4)**	**2,024.23**	**36.75**	**137.30**	**2,877.29**
6	Extra ordinary items	-	-	-	-
7	**Net Profit / (Loss) from Ordinary Activities before Tax(5-6)**	**2,024.23**	**36.75**	**137.30**	**2,877.29**
8	**Tax Expenses**				
	I. Current Tax	516.82	442.63	40.59	732.27
	II. Deferred Tax	4.43	(233.21)	(6.24)	(221.93)
	II. Tax of Earlier Year	-	(0.00)	-	162.15
9	**Net Profit / (Loss) for the Period (7-8)**	**1,502.98**	**(172.67)**	**102.96**	**2,204.79**
10	**Other Comprehensive Income (net off Tax)**				
	Remeasurement of defined benefit plans	-	(8.72)	-	(8.72)
11	**Total Comprehensive Income for the period (9+10)**	**1,502.98**	**(181.39)**	**102.96**	**2,196.08**
12	**Paid up Equity Share Capital**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**
13	Face Value of Equity Shares	**1.00**	**1.00**	**1.00**	**1.00**
14	Earnings per Share (of ₹ 1/- each) :				
	(a) Basic-₹	**0.34**	**(0.04)**	**0.02**	**0.50**
	(b) Diluted-₹	**0.34**	**(0.04)**	**0.02**	**0.50**

NOTES:

1. The above Unaudited Standalone Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on August 12, 2026.
2. The Unaudited Standalone Financial Results are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to confirm with the Unaudited Standalone Financial Results.
3. The Unaudited Standalone Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
4. During the quarter ended June 30, 2026, the Company received 0 investor complaints. Consequently, no investor complaint was pending as on June 30, 2026.
5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
6. The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from October 1, 2025 onwards.

Shukra Pharmaceuticals Limited
REG. NO.: 019079

For and on behalf of the Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH
RAMESHCHANDR
A SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK ,JIVRAJ PARK ROAD ,AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a23be6b9f1e2035fcd9797976bc421cc9df8e8485c129a31d99a204d3e4, pseudonym=5d8b198923c743009cfd88f8b0069402, 2.5.4.20=02731363f2560213d31d8d522de3c70d17f63b08215cc5628399fab337751d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.08.12 14:32:50 +05'30'

Dakshesh Shah
Managing Director
DIN : 00561666

Place: Ahmedabad
Date: August 12, 2026

SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED
CIN: L24231GJ1993PLC019079
3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054
Email : info@shukrapharmaceuticals.com

STANDALONE SEGMENT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2026

(Rs. in Lakhs)

Particulars	QUARTER ENDED			YEAR ENDED
	30-06-2026 (Unaudited)	31-03-2026 (Audited)	30-06-2025 (Unaudited)	31-03-2026 (Audited)
01. Segment Revenue				
Net Sales/income from each segment				
(i) Pharamaceutical segment	2,406.20	725.01	650.08	6,129.10
(ii) Medtech segment	-	-	-	-
Total Segment Revenue	**2,406.20**	**725.01**	**650.08**	**6,129.10**
Less: Inter Segment Revenue	-	-	-	-
Revenue From Operation	**2,406.20**	**725.01**	**650.08**	**6,129.10**
02. Segment Results				
Profit/Loss before tax and interest from each segment				
(i) Pharamaceutical segment	2,067.18	62.58	164.11	2,986.59
(ii) Medtech segment	-	-	-	-
Profit/Loss before tax and interest from each segment	**2,067.18**	**62.58**	**164.11**	**2,986.59**
Add/Less :				
i) Finance Cost	42.95	25.83	26.81	109.30
ii) Other Unallocable Expenditure net off unallocable income	-	-	-	-
Profit Before Tax	**2,024.23**	**36.75**	**137.30**	**2,877.29**
03. Segment Assets				
(i) Pharamaceutical segment	42.81	7.78	29.11	2,094.53
(ii) Medtech segment	0.23	1,154.94	-	1,268.49
Total Segment Assets	**43.04**	**1,162.72**	**29.11**	**3,363.01**
Unallocable Assets	-	-	-	-
Net Segment Assets	**43.04**	**1,162.72**	**29.11**	**3,363.01**
04. Segment Liabilities				
(i) Pharamaceutical segment	2,225.84	1,410.71	431.22	2,308.29
(ii) Medtech segment	-	-	-	-
Total Segment Liabilities	**2,225.84**	**1,410.71**	**431.22**	**2,308.29**
Unallocable Liabilities	-	-	-	-
Net Segment Liabilities	**2,225.84**	**1,410.71**	**431.22**	**2,308.29**
05. Capital Employed (Segment Assets- Segment Liabilities)				
(i) Pharamaceutical segment	**(2,183.03)**	**(1,402.93)**	**(402.11)**	**(213.76)**
(ii) Medtech segment	**0.23**	**1,154.94**	**-**	**1,268.49**

Note:

1.The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from October 1, 2025 onwards.

For and on behalf of the Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH RAMESHCHANDRA SHAH

Dakshesh Shah
Managing Director
DIN : 00561666

Place: Ahmedabad
Date: August 12, 2026

Shukra Pharmaceuticals Limited REG. NO.: 019079

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results of SHUKRA PHARMACEUTICALS LIMITED (the "Company"), for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34, 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of person responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an Audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in as Audit. Accordingly, we do not express an audit opinion.

SHAH SANGHVI & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★
FRN. NO.: 140107W

4. Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Shah Sanghvi & Associates**
Chartered Accountants
FRN: 140107W

SHAH SANGHVI & ASSOCIATES
FRN. NO.: 140107W
CHARTERED ACCOUNTANTS

Ravi Shah
Partner
Membership No: 149091
UDIN: 26149091SRBZBO4699

Place: Ahmedabad
Date: August 12, 2026

SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED
CIN: L24231GJ1993PLC019079
3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054
Email : info@shukrapharmaceuticals.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Sr. No.		Particulars	QUARTER ENDED			YEAR ENDED
			30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1		**Income from Operations**				
	I	Revenue from Operations	2,352.23	632.41	539.11	5,672.74
		(a) Net Sales/ Income from Operations	**2,352.23**	**632.41**	**539.11**	**5,672.74**
	II	Other Income	53.97	94.72	110.97	458.48
		Total Income from Operations (I+II)	**2,406.20**	**727.13**	**650.08**	**6,131.22**
2		**Expenses**				
		(a) Cost of materials consumed	125.46	669.03	(124.85)	1,945.02
		(b) Purchase of Stock-in Trade	-	-	-	-
		(c) Changes in inventories of finished goods, work-in-progress and stock in trade	(279.00)	(75.00)	201.88	(360.12)
		(d) Employee Benefit Expenses	438.87	37.18	182.49	703.72
		(e) Finance Cost	42.95	25.83	26.81	109.30
		(f) Depreciation & Amortisation Expenses	108.25	100.75	78.72	344.27
		(g) Other Expenses	152.49	(68.81)	147.71	510.34
		Total Expenses	**589.02**	**688.98**	**512.78**	**3,252.53**
3		**Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)**	**1,817.18**	**38.15**	**137.30**	**2,878.69**
4		Exceptional Items	-	-	-	-
5		**Profit / (Loss) before Extra ordinary items and Tax (3-4)**	**1,817.18**	**38.15**	**137.30**	**2,878.69**
6		Extra ordinary items	-	-	-	-
7		**Net Profit / (Loss) from Ordinary Activities before Tax(5-6)**	**1,817.18**	**38.15**	**137.30**	**2,878.69**
8		**Tax Expenses**				
		I. Current Tax	516.90	442.99	40.59	732.62
		II. Deferred Tax	4.43	150.87	(6.24)	162.15
		II. Tax of Earlier Year	-	(384.08)	-	(221.93)
9		**Net Profit / (Loss) for the Period (7-8)**	**1,295.85**	**(171.62)**	**102.96**	**2,205.84**
10		**Other Comprehensive Income (net off Tax)**				
		Remeasurement of defined benefit plans	-	(11.65)	-	(11.65)
		Prior Period Adjustments & Expenses	-	2.93	-	2.93
11		**Total Comprehensive Income for the period (9+10)**	**1,295.85**	**(180.34)**	**102.96**	**2,197.13**
12		**Paid up Equity Share Capital**	**4,378.79**	**4,378.79**	**4,378.79**	**4,378.79**
13		Face Value of Equity Shares	**1.00**	**1.00**	**1.00**	**1.00**
14		Earnings per Share (of ₹ 1/- each) :				
		(a) Basic-₹	**0.30**	**(0.04)**	**0.02**	**0.50**
		(b) Diluted-₹	**0.30**	**(0.04)**	**0.02**	**0.50**

NOTES:

1. The above Unaudited Consolidated Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its
2. The Unaudited Consolidated Financial Results are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to confirm with the Unaudited Consolidated Financial Results.
3. The Unaudited Consolidated Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
4. During the quarter ended June 30, 2026, the Company received 0 investor complaints. Consequently, no investor complaint was pending as on June 30, 2026.
5. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
6. The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from October 1, 2025 onwards.

For and on behalf of the Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH RAMESHCHANDRA SHAH

Shukra Pharmaceuticals Limited REG. NO.: 019079

Dakshesh Shah
Managing Director
DIN : 00561666

Place: Ahmedabad
Date: August 12, 2026

CIN: L24231GJ1993PLC019079
3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054
Email : info@shukrapharmaceuticals.com

CONSOLIDATED SEGMENT INFORMATION FOR THE QUARTER ENDED JUNE 30, 2026

(Rs. in Lakhs)

Particulars	QUARTER ENDED			YEAR ENDED
	6/30/2026 (Unaudited)	3/31/2026 (Audited)	6/30/2025 (Unaudited)	31-03-2026 (Audited)
01. Segment Revenue				
Net Sales/income from each segment				
(i) Pharamaceutical segment	2,406.20	725.01	650.08	6,129.10
(ii) Medtech segment	-	-	-	-
Total Segment Revenue	**2,406.20**	**725.01**	**650.08**	**6,129.10**
Less: Inter Segment Revenue	-	-	-	-
Revenue From Operation	**2,406.20**	**725.01**	**650.08**	**6,129.10**
02. Segment Results				
Profit/Loss before tax and interest from each segment				
(i) Pharamaceutical segment	1,860.13	62.58	164.11	2,986.59
(ii) Medtech segment	-	-	-	-
Profit/Loss before tax and interest from each segment	**1,860.13**	**62.58**	**164.11**	**2,986.59**
Add/Less :				
i) Finance Cost	42.95	25.83	26.81	109.30
ii) Other Unallocable Expenditure net off unallocable income	-	-	-	-
Profit Before Tax	**1,817.18**	**36.75**	**137.30**	**2,877.29**
03. Segment Assets				
(i) Pharamaceutical segment	114.39	7.78	29.11	2,094.53
(ii) Medtech segment	0.23	1,154.94	-	1,268.49
Total Segment Assets	**114.62**	**1,162.72**	**29.11**	**3,363.01**
Unallocable Assets	-	-	-	-
Net Segment Assets	**114.62**	**1,162.72**	**29.11**	**3,363.01**
04. Segment Liabilities				
(i) Pharamaceutical segment	2,408.60	1,410.71	431.22	2,308.29
(ii) Medtech segment	-	-	-	-
Total Segment Liabilities	**2,408.60**	**1,410.71**	**431.22**	**2,308.29**
Unallocable Liabilities	-	-	-	-
Net Segment Liabilities	**2,408.60**	**1,410.71**	**431.22**	**2,308.29**
05. Capital Employed (Segment Assets- Segment Liabilities)				
(i) Pharamaceutical segment	**(2,294.21)**	**(1,402.93)**	**(402.11)**	**(213.76)**
(ii) Medtech segment	**0.23**	**1,154.94**	**-**	**1,268.49**

Note:

1.The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from October 1, 2025 onwards.

For and on behalf of the Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

Shukra Pharmaceuticals Limited
REG. NO.: 019079

DAKSHESH
RAMESHCHAN
DRA SHAH

Digitally signed by DAKSHESH RAMESHCHANDRA SHAH
DN: c=IN, postalCode=380051, st=GUJARAT, street=27,JAGANNATH PARK ,JIVRAJ PARK ROAD ,AHMEDABAD,OCTROI NAKA ,380051, l=AHMEDABAD, o=Personal, serialNumber=3ba36a23be6b9f1e2035fcd9797976bc421cc9df8e8485c129a31d99a204d3e4, pseudonym=5d8b198923c743009cfd88f8b0069402, 2.5.4.20=02731363f2560213d31d8d522de3c70d17f63b08215cc5628399fab337751d60, email=DAKSHESHSHAH9@GMAIL.COM, cn=DAKSHESH RAMESHCHANDRA SHAH
Date: 2026.08.12 14:33:46 +05'30'

Dakshesh Shah
Managing Director
DIN : 00561666

Place: Ahmedabad
Date: August 12, 2026

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results of SHUKRA PHARMACEUTICALS LIMITED ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 (the "Statement"), attached herewith being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Listing Regulations"), as amended (the "Listing Regulations").

2. Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34, 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. A review of Interim Financial Information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the SEBI Listing Regulations, as amended, to the extent applicable.

4. The Statement includes the result of the following entities:

   - **Holding Company**
     a) SHUKRA PHARMACEUTICALS LIMITED

   - **Subsidiaries / Body Corporates**
     a) SHUKRA DIABETES TECHNOLOGIES PRIVATE LIMITED
     b) SHUKRA HEALTH TECH PRIVATE LIMITED
     c) SHUKRA ROBOTICS PRIVATE LIMITED
     d) SHUKRA WOUNDCARE PRIVATE LIMITED

SHAH SANGHVI & ASSOCIATES ★ CHARTERED ACCOUNTANTS ★
FRN. NO.: 140107W

5. Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the statement is not modified in respect of the above matters with respect to our reliance on the unaudited interim financial result and information provided by the Management.

For **Shah Sanghvi & Associates**
Chartered Accountants
FRN: 140107W

SHAH SANGHVI & ASSOCIATES
FRN. NO.: 140107W
CHARTERED ACCOUNTANTS

Ravi Shah
Partner
Membership No: 149091
UDIN: 26149091BJBJSJ1477

Place: Ahmedabad
Date: August 12, 2026